Liu Liang, Wang Qiong, Zhang Yan, Liang Jingqi, Liu Peilong, Zhao Hongmou
Department of Foot and Ankle Surgery, Honghui Hospital of Xi'an Jiaotong University, Xi'an, China.
Front Pharmacol. 2023 Apr 12;14:1160278. doi: 10.3389/fphar.2023.1160278. eCollection 2023.
Charcot neuroarthropathy (CN) is a chronic, destructive, and painless damage of the skeletal system that affects the life quality of patients. CN, with an unclear mechanism, is characterized with invasive destruction of bones and a serious abnormality of bone metabolism. Unfortunately, development of an effective prevention and treatment strategy for CN is still a great challenge. Of note, recent studies providing an insight into the molecular mechanisms of bone metabolism and homeostasis have propelled development of novel CN therapeutic strategies. Therefore, this review aims to shed light on the pathogenesis, diagnosis, and treatment of CN. In particular, we highlight the eminent role of the osteoprotegerin (OPG)-receptor activator of nuclear factor-κB (RANK)-RANK ligand (RANKL) system in the development of CN. Furthermore, we summarize and discuss the diagnostic biomarkers of CN as well as the potential pharmacological mechanisms of current treatment regimens from the perspective of bone metabolism. We believe that this review will enhance the current state of knowledge on the diagnosis, prevention, and therapeutic efficacy of CN.
夏科氏神经关节病（CN）是一种慢性、破坏性且无痛的骨骼系统损伤，会影响患者的生活质量。CN的发病机制尚不清楚，其特征是骨骼的侵袭性破坏和骨代谢的严重异常。不幸的是，开发一种有效的CN预防和治疗策略仍然是一个巨大的挑战。值得注意的是，最近对骨代谢和稳态分子机制的研究推动了新型CN治疗策略的发展。因此，本综述旨在阐明CN的发病机制、诊断和治疗。特别是，我们强调了骨保护素（OPG）-核因子κB受体激活剂（RANK）-RANK配体（RANKL）系统在CN发展中的重要作用。此外，我们从骨代谢的角度总结并讨论了CN的诊断生物标志物以及当前治疗方案的潜在药理机制。我们相信，本综述将提升目前对CN诊断、预防和治疗效果的认识水平。
